FY2017 Earnings Forecast for Seres Therapeutics, Inc. (MCRB) Issued By Cantor Fitzgerald
Seres Therapeutics, Inc. (NASDAQ:MCRB) – Stock analysts at Cantor Fitzgerald upped their FY2017 EPS estimates for shares of Seres Therapeutics in a report issued on Tuesday. Cantor Fitzgerald analyst W. Tanner now forecasts that the biotechnology company will post earnings per share of ($2.45) for the year, up from their prior estimate of ($2.62). Cantor Fitzgerald currently has a “Buy” rating and a $16.00 target price on the stock. Cantor Fitzgerald also issued estimates for Seres Therapeutics’ FY2018 earnings at ($2.92) EPS.
Other analysts also recently issued reports about the company. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a research note on Friday, May 19th. Zacks Investment Research downgraded Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $19.00 price target (up from $15.00) on shares of Seres Therapeutics in a research note on Friday, August 4th. Canaccord Genuity set a $20.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, ValuEngine upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $16.17.
WARNING: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/10/fy2017-earnings-forecast-for-seres-therapeutics-inc-mcrb-issued-by-cantor-fitzgerald.html.
Seres Therapeutics (NASDAQ:MCRB) opened at 13.53 on Thursday. Seres Therapeutics has a 52-week low of $8.85 and a 52-week high of $15.09. The firm’s market capitalization is $546.48 million. The stock’s 50 day moving average price is $12.44 and its 200 day moving average price is $10.64.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by $0.10. The business had revenue of $3 million for the quarter, compared to analyst estimates of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The company’s revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.70) earnings per share.
A number of institutional investors have recently modified their holdings of MCRB. Vanguard Group Inc. increased its position in shares of Seres Therapeutics by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock worth $17,645,000 after buying an additional 103,456 shares during the last quarter. Spark Investment Management LLC bought a new position in shares of Seres Therapeutics during the first quarter worth approximately $613,000. JPMorgan Chase & Co. increased its position in shares of Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock worth $4,172,000 after buying an additional 50,860 shares during the last quarter. American Century Companies Inc. bought a new position in shares of Seres Therapeutics during the first quarter worth approximately $447,000. Finally, Tudor Investment Corp ET AL increased its position in shares of Seres Therapeutics by 162.4% in the first quarter. Tudor Investment Corp ET AL now owns 50,188 shares of the biotechnology company’s stock worth $566,000 after buying an additional 31,062 shares during the last quarter. Institutional investors own 75.31% of the company’s stock.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.